menu
    • menu

    Company profile for Rein Therapeutics

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rein Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class therapies for orphan pulmonary and fibrosis diseases. Its lead candidate, LTI-03, is a novel peptide targeting epithelial cell survival and profibrotic signaling, with a Phase 2 trial planned in 2025 for idiopathic pulmonary fibrosis. LTI-01, Rein’s second candidate, is a proenzyme for loculated pleural effusions and has completed Phase...
    Rein Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class therapies for orphan pulmonary and fibrosis diseases. Its lead candidate, LTI-03, is a novel peptide targeting epithelial cell survival and profibrotic signaling, with a Phase 2 trial planned in 2025 for idiopathic pulmonary fibrosis. LTI-01, Rein’s second candidate, is a proenzyme for loculated pleural effusions and has completed Phase 1b and 2a trials. It holds Orphan Drug Designation in the U.S. and EU and Fast Track status in the U.S.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Rein TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12407 N Mo Pac Expy, 390, Austin, Texas 78758
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.reintx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rein-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rein Therapeutics Gets EU Approval To Initiate LTI-03 Ph2 Trial
    Rein Therapeutics Gets EU Approval To Initiate LTI-03 Ph2 Trial

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164036/28652/en/Rein-Therapeutics-Receives-European-Regulatory-Approval-to-Initiate-Phase-2-Trial-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    Rein Publishes Translational Data on IPF Novel Therapy
    Rein Publishes Translational Data on IPF Novel Therapy

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151534/28652/en/Rein-Therapeutics-Announces-Publication-of-New-Translational-Data-in-iScience-on-Company-s-Novel-Therapy-for-Idiopathic-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    Rein Therapeutics Wins Nod for Ph 2 LTI-03 in Pulmonary Fibrosis
    Rein Therapeutics Wins Nod for Ph 2 LTI-03 in Pulmonary Fibrosis

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/19/3135623/28652/en/Rein-Therapeutics-Wins-U-K-Approval-to-Launch-Phase-2-Clinical-Trial-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Rein Therapeutics to Present IPF Insights at IPF Summit 2025
    Rein Therapeutics to Present IPF Insights at IPF Summit 2025

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133952/28652/en/Rein-Therapeutics-to-Present-Novel-IPF-Science-and-Clinical-Development-Insights-at-IPF-Summit-2025.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share
    Rein Therapeutics Secures Up to $21M in Flexible Financing
    Rein Therapeutics Secures Up to $21M in Flexible Financing

    30 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/30/3124071/28652/en/Rein-Therapeutics-Enters-into-Agreements-for-up-to-21-Million-in-Flexible-Financing.html

    GLOBENEWSWIRE
    30 Jul 2025
    Share Share
    Rein Therapeutics Adjourns Annual Stockholders Meeting
    Rein Therapeutics Adjourns Annual Stockholders Meeting

    24 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rein-therapeutics-announces-adjournment-of-annual-meeting-of-stockholders-302489779.html

    PR NEWSWIRE
    24 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search